Lisa Michelle Kallebo - 13 Feb 2026 Form 4 Insider Report for ADC Therapeutics SA (ADCT)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
18 Feb 2026, 17:44:04 UTC
Prior SEC filing
09 Dec 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Lisa Kallebo

Key filing fact

Lisa Michelle Kallebo filed Form 4 for ADC Therapeutics SA (ADCT) on 18 Feb 2026.

Key facts

  • This page summarizes Lisa Michelle Kallebo's Form 4 filing for ADC Therapeutics SA (ADCT).
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 18 Feb 2026, 17:44.

Change

  • Previous filing in this sequence was filed on 09 Dec 2025.
  • Current net transaction value: +$229,293.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002000724 Primary reporting owner

Kallebo Lisa Michelle

Relationship
Chief Accounting Officer
Address
430 MOUNTAIN AVENUE, SUITE 404, NEW PROVIDENCE
Signature
/s/ Lisa Kallebo
Signature date
18 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADCT transaction

Common Shares

Award

Transaction value
$250,971
Shares
+62,900
Change %
+89%
Price
$3.99
Shares after
133,657
Date
13 Feb 2026
Ownership
Direct
Footnotes
F1
ADCT transaction

Common Shares

Tax liability

Transaction value
$21,678
Shares
-5,433
Change %
-4.1%
Price
$3.99
Shares after
128,224
Date
13 Feb 2026
Ownership
Direct
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents Common Shares to be delivered in settlement of a restricted share unit award which vests one-third on the first anniversary of the grant date, which grant date is February 13, 2026, and then one-third on each anniversary date thereafter, upon continued service through the designated vesting event.

Footnote F2

Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .